Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Adopted by German Lighting Brand WALTRON for Aquarium Lighting
29.10.2019 20:08:00 EET | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that WALTRON, specialists in LED lighting systems for aquariums and terrariums based in Lower Saxony, Germany, has adopted Seoul Semiconductor’s SunLike Series natural spectrum LEDs for daytime® Pendix, WALTRON’s aquarium lighting solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191029005896/en/
Seoul Semiconductor’s SunLike Series natural spectrum LEDs for aquarium lighting of German brand WALTRON (Photo: Business Wire)
Indoor aquariums are full of colorful corals, fish, and water plants living in an ecosystem similar to nature. Direct sunlight is typically avoided in these spaces in order to limit the reproduction of algae. This is necessary to keep water from becoming turbid and harming the ecological balance of the aquarium system. As a result, lighting solutions play an important role in maintaining growth without disturbing the ecological cycle.
The daytime Pendix is a matrix LED module with 9 different color temperatures and features a customized spectral lighting design that closely matches the spectrum of natural sunlight enabled by SunLike Series LEDs. Different light colors such as white, blue, and red can be combined in the module to provide the optimal lighting solution for both saltwater aquariums and freshwater aquariums.
Sunlight has always played an important role with plant growth in nature. SunLike Series natural spectrum LEDs are similar to sunlight which radiate a uniform amount of energy at all wavelengths, including infrared and ultraviolet as the optimal light source for plant growth. The technology lowers the light peaks of red, green and blue to be more similar to sunlight’s spectral curve in order to provide a better growth formula than what is common in conventional LEDs. This results in a more natural and healthy environment for fish, plants, and corals while further decreasing algae growth on glass.
Light sources with SunLike Series LEDs more accurately show the color of objects as they would appear in natural sunlight. Optimized to natural light spectra and color rendering of CRI-97 (close to CRI-100 of sunlight), and higher than the CRI-80 of conventional LEDs, SunLike Series LEDs deliver more significant benefits in vivid color, contrast detail, and quality of light consistency. These qualities can be vital to aquariums, enabling the owners to more accurately observe and attend to the overall growth and health status of fish.
“We are pleased to expand this aquarium LED lighting portfolio. Our SunLike Series natural spectrum LEDs as healthy light sources will offer the considerable benefits for better growth of fishes and plants in aquarium, compared to conventional LEDs,” said Carlo Romiti, Europe sales Vice President of Seoul Semiconductor. “Seoul Semiconductor will continue to support the needs of customers with a range of innovative LED lighting solutions.”
Seoul Semiconductor developed SunLike Series natural spectrum LEDs in collaboration with Toshiba Materials’ TRI-R spectrum technology in 2017 as the first LED light source to closely match the spectrum of natural sunlight.
To learn more about daytime Pendix by WALTRON, please visit:
http://daytime.de/led-systeme-pendix
To learn more about the SunLike Series natural spectrum LEDs, please visit: http://www.seoulsemicon.com/en/technology/Sunlike/
# # #
About WALTRON
WALTRON specializes in innovative LED lighting systems that highlight the natural beauty of animals and plants in aquariums and terrariums brilliantly. Its daytime® brand delivers lighting solutions for the demanding aquarium owner. We invite you to discover the many possibilities of the daytime® product lines: matrix, eco, cluster and cluster control. For more information, please visit http://daytime.de/.
About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191029005896/en/
Contact information
Seoul Semiconductor Inc.
Jeonghee Kim
Tel: +82-70-4391-8311
Email: jeonghee.kim@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
